Impact ledger
bluebird bio, Inc. (BLUE): the developments shaping its investment case
Follow the evidence affecting bluebird bio, Inc.. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research bluebird bio, Inc. · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-09 · 3 reports
CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump
Channel: Indirect competitive pressure and market dynamics for gene therapies in similar indications. Validation of gene therapy market but also increased competition.
mixed· 3-12m
2026-09-16
CAR-T oncology market expands as ALL and lymphoma therapies target long-term growth
Channel: Indirect benefit from overall market expansion and increased investor interest in cell therapy, potentially improving access to capital and future commercialization prospects for their gene therapy pipeline, which shares technological similarities and patient populations.
Bullish· 1-5y
2026-09-09
FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy Casgevy
Channel: Increased investor attention and potential for sector-wide re-rating of gene therapy companies, but also increased competitive pressure in the broader gene therapy space.
mixed· 1-3m
Event impact log
9 events mapped to BLUE since 2026-09-01. Evidence through 2026-09-24.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-24 | Kyverna Therapeutics, Inc. to Complete Rolling BLA Submission for Miv-cel in Q4 2026 | Second-order effect: Bluebird bio is also a gene therapy company. Kyverna's progress in a complex therapeutic area could indirectly influence investor perception of the broader gene/cell therapy space, potentially affecting sentiment for companies like BLUE, especially regarding regulatory pathways | watch | 3-12m | 0.25 |
| 2026-09-16 | CAR-T oncology market expands as ALL and lymphoma therapies target long-term growth | Indirect benefit from overall market expansion and increased investor interest in cell therapy, potentially improving access to capital and future commercialization prospects for their gene therapy pipeline, which shares technological similarities and patient populations. | Bullish | 1-5y | 0.40 |
| 2026-09-12 | Cellectis Schedules September 14 Business Update on Gene Editing and CAR T Pipeline | Second-order effect: Investor sentiment in the broader cell and gene therapy sector, particularly for companies with complex manufacturing or regulatory challenges. | mixed | 1-3m | 0.20 |
| 2026-09-12 | Cellectis Schedules September 14 Business and CAR T Pipeline Update | Second-order effect through sector sentiment. bluebird bio operates in the gene therapy and cell therapy space, making it sensitive to broader industry news. | watch | 1-5d | 0.20 |
| 2026-09-09 | CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump | Indirect competitive pressure and market dynamics for gene therapies in similar indications. Validation of gene therapy market but also increased competition. | mixed | 3-12m | 0.50 |
| 2026-09-09 | CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients Aged 2+ | Increased competitive pressure in the gene therapy market for blood disorders, potentially impacting market share or pricing power for competing therapies. | Bearish | 3-12m | 0.40 |
| 2026-09-09 | CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M | Indirect competitive pressure and market sentiment shift within the gene therapy space for sickle cell disease and beta-thalassemia. | mixed | 3-12m | 0.40 |
| 2026-09-09 | FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy Casgevy | Increased investor attention and potential for sector-wide re-rating of gene therapy companies, but also increased competitive pressure in the broader gene therapy space. | mixed | 1-3m | 0.40 |
| 2026-09-01 | Valion Bio, Inc. Follow-On — $7.7M | Similar to VCEL, bluebird bio operates in the gene and cell therapy space. While Valion Bio's specific focus isn't detailed, any financing in this broader, capital-intensive biotech sector could be seen as a minor signal of market activity or potential future competition. | watch | 3-12m | 0.20 |
Continue this research
Build your bluebird bio, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the BLUE entity page →